The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients - 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24-3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

4th Department of Internal Medicine Hematology University Hospital Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Complejo Asistencial de Avila Avila Spain

Cota Inc Boston MA USA

Dana Farber Cancer Institute Harvard Medical School Boston MA USA

Department of Experimental Hematology Medical University of Lodz Lodz Poland

Department of Experimental Hematology Medical University of Lublin Lublin Poland

Department of Hematology and Stem Cell Transplantation South Pest Central Hospital National Institute of Hematology and Infectology Budapest Hungary

Department of Hematology Collegium Medicum in Bydgoszcz Nicolaus Copernicus University Toruń Poland

Department of Hematology Fundeni Clinical Institute University of Medicine and Pharmacy Carol Davila Bucharest Romania

Department of Hematology Jagiellonian University Medical College Cracow Poland

Department of Hematology Oncology and Internal Diseases Warsaw Medical University Warsaw Poland

Department of Hematology Oncology Medstar Georgetown University Hospital Washington NW USA

Department of Hematology SPZOZ ZSM Chorzow Poland

Department of Hematology St John's Cancer Center Lublin Poland

Department of Hematology UZ Leuven Leuven Belgium

Department of Hematology Wroclaw Medical University Wroclaw Poland

Department of Infectious and Tropical Diseases Jagiellonian University Medical College Cracow Poland

Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany

Department of Medicine Queen Mary Hospital University of Hong Kong Hong Kong Hong Kong

Department of Medicine Warren Alpert Medical School Brown University Providence RI USA

Departments of Hematology Amyloidosis and Myeloma Unit Hospital Clínic IDIBAPS University of Barcelona Barcelona Spain

Division of Hematology and Medical Oncology Knight Cancer Institute Oregon Health and Science University Portland OR USA

Division of Hematology Department of Medical Science Surgery and Neuroscience University of Siena Siena Italy

Division of Hematology Oncology Department of Medicine Medical College of Wisconsin Milwaukee WI USA

Hematology Unit AO Cosenza Cosenza Italy

Hospital Universitario de Salamanca Instituto Biosanitario de Salamanca Salamanca Spain

Icahn School of Medicine at Mount Sinai Tisch Cancer Institute New York NY USA

Institute of Cardiology Jagiellonian University Medical College Cracow Poland

Institute of Hematology and Transfusion Medicine Warsaw Poland

John Theurer Cancer Center Hackensack UMC Hackensack NJ USA

Maria Sklodowska Curie National Institute of Oncology Cracow Poland

Tel Aviv Sourasky Medical Center Tel Aviv Israel and the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Weill Cornell Medical College New York NY USA

000      

00000naa a2200000 a 4500

001      

bmc21020310

003      

CZ-PrNML

005      

20210830101938.0

007      

ta

008      

210728s2020 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1080/10428194.2020.1749605 $2 doi

035    __

$a (PubMed)32306794

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Goldman-Mazur, Sarah $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland

245    10

$a Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients / $c S. Goldman-Mazur, A. Jurczyszyn, JJ. Castillo, A. Waszczuk-Gajda, N. Grząśko, J. Radocha, M. Bittrich, KM. Kortüm, A. Gozzetti, L. Usnarska-Zubkiewicz, JD. Valls, DS. Jayabalan, R. Niesvizky, J. Kelman, D. Coriu, L. Rosiñol, Ł. Szukalski, V. González-Calle, MV. Mateos, K. Jamroziak, I. Hus, I. Avivi, Y. Cohen, P. Mazur, A. Suska, A. Chappell, D. Madduri, S. Chhabra, A. Kleman, P. Hari, M. Delforge, P. Robak, M. Gentile, I. Kozłowska, SL. Goldberg, J. Czepiel, M. Długosz-Danecka, R. Silbermann, AJ. Olszewski, P. Barth, G. Mikala, CS. Chim, DH. Vesole

520    9_

$a The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients - 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24-3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).

650    _2

$a přežití po terapii bez příznaků nemoci $7 D018572

650    12

$a transplantace hematopoetických kmenových buněk $7 D018380

650    _2

$a lidé $7 D006801

650    12

$a mnohočetný myelom $x diagnóza $x genetika $x terapie $7 D009101

650    _2

$a prognóza $7 D011379

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a autologní transplantace $7 D014182

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

700    1_

$a Jurczyszyn, Artur $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland

700    1_

$a Castillo, Jorge J $u Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

700    1_

$a Waszczuk-Gajda, Anna $u Department of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland

700    1_

$a Grząśko, Norbert $u Department of Experimental Hematology, Medical University of Lublin, Lublin, Poland $u Department of Hematology, St. John's Cancer Center, Lublin, Poland

700    1_

$a Radocha, Jakub $u 4th Department of Internal Medicine - Hematology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

700    1_

$a Bittrich, Max $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

700    1_

$a Kortüm, Klaus Martin $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

700    1_

$a Gozzetti, Alessandro $u Division of Hematology, Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy

700    1_

$a Usnarska-Zubkiewicz, Lidia $u Department of Hematology, Wroclaw Medical University, Wroclaw, Poland

700    1_

$a Valls, Julio D $u Complejo Asistencial de Avila, Avila, Spain

700    1_

$a Jayabalan, David S $u Weill Cornell Medical College, New York, NY, USA

700    1_

$a Niesvizky, Ruben $u Weill Cornell Medical College, New York, NY, USA

700    1_

$a Kelman, Julia $u Weill Cornell Medical College, New York, NY, USA

700    1_

$a Coriu, Daniel $u Department of Hematology, Fundeni Clinical Institute, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania

700    1_

$a Rosiñol, Laura $u Departments of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

700    1_

$a Szukalski, Łukasz $u Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland

700    1_

$a González-Calle, Veronica $u Hospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain

700    1_

$a Mateos, María-Victoria $u Hospital Universitario de Salamanca/Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain

700    1_

$a Jamroziak, Krzysztof $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland

700    1_

$a Hus, Iwona $u Department of Experimental Hematology, Medical University of Lublin, Lublin, Poland $u Department of Hematology, St. John's Cancer Center, Lublin, Poland $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland

700    1_

$a Avivi, Irit $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

700    1_

$a Cohen, Yael $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

700    1_

$a Mazur, Piotr $u Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland

700    1_

$a Suska, Anna $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland

700    1_

$a Chappell, Aimee $u Department of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, NW, USA

700    1_

$a Madduri, Deepu $u Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA

700    1_

$a Chhabra, Saurabh $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

700    1_

$a Kleman, Ariel $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

700    1_

$a Hari, Parameswaran $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

700    1_

$a Delforge, Michel $u Department of Hematology, UZ Leuven, Leuven, Belgium

700    1_

$a Robak, Paweł $u Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland

700    1_

$a Gentile, Massimo $u Hematology Unit, AO Cosenza, Cosenza, Italy

700    1_

$a Kozłowska, Izabela $u Department of Hematology, SPZOZ ZSM, Chorzow, Poland

700    1_

$a Goldberg, Stuart L $u John Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA $u Cota Inc, Boston, MA, USA

700    1_

$a Czepiel, Jacek $u Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Cracow, Poland

700    1_

$a Długosz-Danecka, Monika $u Maria Sklodowska-Curie National Institute of Oncology, Cracow, Poland

700    1_

$a Silbermann, Rebecca $u Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

700    1_

$a Olszewski, Adam J $u Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA

700    1_

$a Barth, Peter $u Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA

700    1_

$a Mikala, Gabor $u Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary

700    1_

$a Chim, Chor S $u Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong

700    1_

$a Vesole, David H $u John Theurer Cancer Center, Hackensack UMC, Hackensack, NJ, USA

773    0_

$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 61, č. 8 (2020), s. 1885-1893

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32306794 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830101937 $b ABA008

999    __

$a ok $b bmc $g 1690987 $s 1140756

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 61 $c 8 $d 1885-1893 $e 20200419 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140

LZP    __

$a Pubmed-20210728